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Purpose: This study was conducted to determine the incidence, risk factors, and treatment for retinop-
athy of prematurity (ROP) among very low birth weight (VLBW) infants.
Methods: This work is a retrospective, observational analysis of all VLBW infants managed at National
Taiwan University Hospital from 2002 to 2005.
Results: The chart data of 96 VLBW infants were reviewed. Seven of the 96 infants (7.3%) were noted to
have no ROP, while 18 infants (18.7%) had minor ROP (stage 1 and stage 2 ROP) and 71 infants (74%) had
severe ROP (greater than stage 2 ROP). With lower gestational age, lower birth body weight, greater
degree of respiratory distress syndrome, prolonged use of oxygen, and without maternal history of
antenatal steroid use, the incidence of severe ROP (greater than stage 2) increased signiﬁcantly
(p < 0.001, p < 0.001, p ¼ 0.01, p < 0.001, and p ¼ 0.03, respectively).
Conclusion: More severe ROP may correlate with lower gestational age, lower birth body weight, and
longer oxygen use. Use of antenatal steroid would decrease the incidence of severe ROP.
Copyright  2012, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Retinopathy of prematurity (ROP), originally reported in 1942, is
a disease characterized by abnormal vascular development of retina
and is the main cause of visual impairment in premature infants.1
The increased survival of extremely low birth weight (ELBW)
infants in recent years, due to advances in neonatal care, has
produced a population of infants at very high risk of developing
ROP.2e5
A high concentration of oxygen therapy was previously thought
to be the major contributory factor in the development of ROP.6
However, some reports found that not all premature infants
develop ROP even after oxygen therapy.7 Several factors may
increase the risk of ROP, especially those associated with short
gestational age and low birth body weight, mechanical ventilation,
neonatal sepsis, intraventricular hemorrhage, and use of antenatal
and postnatal steroid.8e11
The objective of this study was to determine the incidence of
ROP and to evaluate the possible risk factors associated with theg).
e Ophthalmologic Society of Taiwdevelopment of ROP among very low birth weight (VLBW;
1500 g) infants.12
2. Patients and methods
This work was a retrospective, observational analysis of VLBW
infants who had been screened for ROP. All VLBW neonates who
had been admitted to the neonatal intensive care unit in National
Taiwan University Hospital from January 2002 to December 2005
and had been screened for ROP by an ophthalmologist, were
eligible for the study. We reviewed the following data from charts
for these infants: gender, gestational age, birth body weight,
delivery type, maternal history such as preeclampsia and prema-
ture rupture of amniotic membrane (PROM), duration of oxygen
use, use of antenatal steroid, stage of ROP, and treatment for
threshold ROP. Gestational age was expressed in weeks, ignoring
any additional days (e.g., 25 weeks 0 days through 25 weeks 6 days
expressed as 25 weeks). Infants whose data were not complete or
who did not survive were excluded. All these infants underwent
initial fundus examination by an ophthalmologist, and the
following examination was according to the severity of ROP. The
classiﬁcation of ROPwas based on the International Classiﬁcation of
ROP.13 In our study, we formed three groups to denote the differentan. Published by Elsevier Taiwan LLC. All rights reserved.
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ROP, and severe ROP with greater than stage 2 ROP.
To determine the incidence and risk factors of ROP among VLBW
infants, statistical analysis was performed using the Statistical
Package for Social Science program. Comparison of risk factors for
different severity of ROP was evaluated using multiple regression
analysis. A p value less than 0.05 was considered statistically
signiﬁcant.
3. Results
From January 2002 to December 2005, 121 VLBW infants
admitted to the neonatal intensive care unit of National Taiwan
University Hospital had undergone ophthalmic examination for
ROP. Five of 121 VLBW infants did not survive due to poor systemic
condition such as congenital anomaly, severe pulmonary disease,
and systemic sepsis. Twenty of the surviving 116 VLBW infants
were noted to have incomplete chart data for our established items
for study. Overall, 96 VLBW infants were enrolled in this retro-
spective study, of which 44 were born at National Taiwan Univer-
sity Hospital, while the other 52 infants were transferred from
other hospitals due to severe systemic condition or were being
treated for further management of severe ROP.
Of the 96 VLBW infants, 48 were boys and 48 were girls. The
gestational age ranged from 22 to 32 weeks (mean, 26.8 weeks),
and the birth body weight ranged from 420 to 1500 g (mean,
952.1 g). A total of 38 infants (39.5%) were delivered by normal
spontaneous delivery and the remaining 58 infants (60.5%) by
cesarean section. Among the 96 VLBW infants, 28 (29.2%) babies
were from twin pregnancies and three (3.1%) were from a triplet
pregnancy. Thirteen infants (13.5%) were noted to have a maternal
history of preeclampsia, while 26 infants (27.1%) had a maternalTable 1
Incidence of retinopathy of prematurity (ROP) by patient characteristics.
n No ROP Stage 2 ROP
Total infants 96 7 (7.3%) 18 (18.7%)
Gender
Boys 48 1 (2.1%) 7 (14.6%)
Girls 48 6 (12.5%) 11 (22.9%)
Gestational age
25 wk 36 0 (0%) 3 (8.4%)
26e28 wk 36 1 (2.8%) 6 (16.7%)
29 wk 24 6 (25%) 8 (33.3%)
Birth body weight
1000 g 60 0 (0%) 9 (15%)
1001e1500 g 36 7 (19.4%) 9 (25%)
Delivery type
NSD 38 1 (2.6%) 5 (13.1%)
C/S 58 6 (10.4%) 13 (22.4%)
Preeclampsia
No 83 6 (7.2%) 13 (15.7%)
Yes 13 1 (7.7%) 5 (38.5%)
PROM
No 70 6 (8.6%) 13 (18.6%)
Yes 26 1 (3.8%) 5 (19.2%)
Respiratory distress syndrome
Grade II 50 7 (14%) 12 (24%)
>Grade II 46 0 (0%) 6 (13.1%)
Oxygen for 3 mo
No 56 7 (12.5%) 14 (25%)
Yes 42 0 (0%) 4 (9.6%)
Antenatal steroid use
No 61 1 (1.6%) 10 (16.5%)
Yes 35 6 (17.1%) 8 (22.9%)
þ p < 0.05, statistically signiﬁcant.
PROM ¼ premature rupture of amniotic membrane.
a Surgery for greater than stage 3 retinopathy of prematurity included the following:history of PROM. Seven of the 96 infants (7.3%) were without ROP,
while 18 infants (18.7%) had minor ROP (stage 1 and stage 2 ROP),
and 71 infants (74%) had severe ROP (greater than stage 2 ROP).
Among the 71 infants with severe ROP, 43 infants were treatedwith
laser therapy for stage 3 ROP and the other 28 infants who had
received laser therapy but still progressed to stage 4 or stage 5 ROP
required surgery such as cryotherapy, scleral buckling, and pars
plana vitrectomy. Among these 28 infants, three were born at
National Taiwan University Hospital, while the other 25 infants
were diagnosed with greater than stage 3 ROP when they were
transferred from other hospitals. Table 1 illustrates the incidence of
retinopathy by patient characteristics.
Gestational age was divided into three age groups: 25, 26e28,
and 29 weeks. Among infants in the 25 weeks group (n ¼ 36),
three (8.4%) had less than stage 2 ROP while 33 (91.6%) had greater
than stage 2 ROP. No infant in this group was noted to have ROP. In
the 26e28 weeks group (n¼ 36), only one infant had no ROP, while
six (16.7%) had less than stage 2 ROP and 29 (80.5%) had greater
than stage 2 ROP. In the29 weeks group (n¼ 24), six (25%) had no
ROP, eight infants (33.3%) had less than stage 2 ROP, and 10 (41.7%)
had greater than stage 2 ROP. We found that with increased
gestational age, the incidence of severe ROP decreased statistically
(p < 0.001).
Birth body weight was divided into two groups: 1000 g
(ELBW) and 1001e1500 g (VLBW). In a total of 60 infants in the
ELBW group, only one infant had no ROP. Night infants (15%) had
milder than stage 2 ROP and 51 infants (85%) had worse than stage
2 ROP. In a total of 36 infants in the VLBW group, seven infants
(19.4%) had no ROP, nine (25%) had milder than stage 2 ROP, and 20
(55.6%) had worse than stage 2 ROP. We found that with increased
birth body weight, the incidence of severe ROP decreased statisti-
cally (p < 0.001).>Stage 2 ROP p
Needs laser Needs surgerya Total
43 (44.8%) 28 (29.2%) 71 (74%)
21 (43.7%) 19 (39.6%) 40 (83.3%) 0.14
22 (45.8%) 9 (18.8%) 31 (64.6%)
17 (47.2%) 16 (44.4%) 33 (91.6%) <0.001þ
21 (58.3%) 8 (22.2%) 29 (80.5%)
6 (25%) 4 (16.7%) 10 (41.7%)
30 (50%) 22 (35%) 52 (85%) <0.001þ
13 (36.2%) 7 (19.4%) 20 (55.6%)
22 (57.9%) 10 (26.4%) 32 (84.2%) 0.22
21 (36.2%) 18 (31%) 39 (67.2%)
39 (46.9%) 25 (36.2%) 64 (77.1%) 0.05
4 (30.7%) 3 (23.1%) 7 (53.8%)
29 (41.4%) 22 (31.4%) 51 (72.8%) 0.99
14 (53.8%) 6 (23.2%) 20 (77%)
24 (48%) 7 (14%) 31 (62%) 0.01þ
19 (41.3%) 21 (45.6%) 40 (86.9%)
24 (42.9%) 9 (16.1%) 33 (59%) <0.001þ
19 (45.2%) 19 (45.2%) 38 (90.4%)
28 (45.9%) 22 (36.1%) 50 (81.9%) 0.03þ
15 (42.9%) 6 (17.1%) 21 (60%)
cryotherapy, scleral buckling, pars plana lensectomy, pars plana vitrectomy.
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distress syndrome (RDS), we found that 62% of infants with less
than Grade II RDS develop severe ROP, but 86.9% infants with
greater than Grade II RDS develop severe ROP (p ¼ 0.01 < 0.05).
Considering the duration of oxygen use, 59% of infants with oxygen
use less than 3 months develop severe ROP, while 90.4% infants
with oxygen use longer than 3 months develop severe ROP
(p < 0.001). Maternal history of preeclampsia and PROM did not
show statistical signiﬁcance with severity of ROP. Considering
antenatal steroid use, 50 of 61 infants (81.9%) whose mothers did
not receive antenatal steroid would develop severe ROP, while 21 of
35 infants (60%) whose mothers had received antenatal steroid
would develop severe ROP. We found that incidence of severe ROP
would decrease with antenatal steroid use (p ¼ 0.03 < 0.05).
4. Discussion
ROP, which was previously called retrolental ﬁbroplasias, is
a disorder of proliferative retinopathy of premature and low birth
weight infants with the extent of the immaturity of the retina
depending mainly on the degree of prematurity at birth.7 It is very
important that at-risk preterm infants should receive timely retinal
examinations before the extent of ROP becomes permanently
destructive.13,14 The Joint Statement of the American Academy of
Pediatrics, Section on Ophthalmology, the American Association for
Pediatric Ophthalmology and Strabismus, and the American
Academy of Ophthalmology recommended that at least two dilated
fundoscopic examinations using binocular indirect ophthalmology
be conducted for all infants with a birth weight of less than 1500 g
or with a gestational age of 30 weeks or less, as well as for selected
infants between 1500 and 2000 g or gestational age of more than
30 weeks with an unstable clinical course.8 The initiation of acute-
phase ROP screening should be based on the infant’s age. Exami-
nations before the 31st week are not recommended because of
possible iatrogenic injuries. The ﬁrst eye examination should
generally be conducted by 31 weeks of postmenstrual age or 4
weeks of chronological age, whichever occurs later.9Sequential
examinations are then generally performed every 1e2 weeks
depending on the extent of ROP until the retina is fully vascularized.
It has been believed for many years that oxygen therapy
increases the risk of ROP in preterm infants. However, ROP can
occur evenwith careful control of oxygen therapy.15e21 RDS caused
by developmental insufﬁciency of surfactant production and
structural immaturity in the lungs is a serious complication of
preterm birth. Infants with greater RDS would be at increased risk
for ROP due to prolonged oxygen use.22 Antenatal steroid admin-
istration has been recommended for pregnancies of 24e34 weeks
of gestation to promote lung maturity in premature delivery and to
decrease the risks of RDS and neonatal death. Higgins et al23 and
Kennedy24 have reported that antenatal use of dexamethasone was
associated with decreased incidence of severe ROP in infants. In our
study, we found that the incidence of severe ROP decreased with
use of antenatal steroid (p ¼ 0.03). Other identiﬁed risk factors of
ROP include sepsis, intraventricular hemorrhage, exposure to light,
blood transfusion, and mechanical ventilation.25,26
Cryotherapy and laser retinopexy have been the preferred
methods of treatment for severeROP since 1988, and thepresence of
threshold disease formed the indication for treatment.27e29
Although the Cryotherapy for ROP study demonstrated outcomes
superior to the untreated natural history of disease, even eyes with
favorable anatomic outcomes still had poor vision over a longer
period. Therewas still 44%prevalenceof adverse functional outcome
at 10 years for cryo-treated eyes.30 Some research studies showed
that many babies who develop ROP subsequently become myopic,
and this myopic tendency is augmented by both cryotherapy andlaser treatment.31e37 However, another study found less myopia in
laser-treated eyes than cryo-treated eyes, probably because the
cryo-treated eyes had shallower anterior chamberdepth and thicker
lens.38 Additional advantages of laser photoablation over cryoa-
blation include reduced postoperative inﬂammation and lower risk
of systemic complications. Therefore, itwas recommended that laser
treatment should be considered the mainstay of treatment for ROP.
Nget al39 andConnollyet al40 reported that long-termstructural and
functional outcomes using laser were superior to those obtained
with cryotherapy. Favorable anatomic results have been reported in
83% of eyes treated with laser, whereas cryotherapy, by contrast,
provided favorable outcomes in only 25% of eyes with zone I
disease.39,40 In comparison to the Cryotherapy for ROP, the Early
Treatment for Retinopathy of Prematurity study demonstrated
a statistically signiﬁcant beneﬁt of earlier treatment.41 The 9-month
data demonstrated a reduction in unfavorable visual outcomes from
19.5% to 14.5%, and a reduction in unfavorable structural outcomes
(deﬁned as retinal folds or detachment) from 15.4% to 9.1% in eyes
that received early treatment.42 The 6-year research data also
demonstrated that early-treated eyes had better structural outcome
compared with conventionally managed eyes (8.9% vs. 15.2% unfa-
vorable outcome).43
In this study, we found that increased gestational age, increased
birth body weight, and maternal history of antenatal steroid use
correlate with decreased incidence of severe ROP. Greater degree of
RDS and prolonged use of oxygen also correlate with increased
incidence of severe ROP. Our analysis shows that 43 of 71 infants
with greater than stage 2 ROP who received laser retinopexy could
be stabilized without progression. However, the other 28 infants
who had received laser therapy still progressed to stage 4 or stage 5
ROP and had to receive surgical intervention, and only 10 of these
28 eyes ﬁnally reached anatomical success with retina attached.
The limitation of this study is that our study population is small
(only 96 VLBW infants), of which 28 infants had stage 4 or stage 5
ROP, three infants were born at National Taiwan University
Hospital, while the other 25 infants were diagnosed with greater
than stage 3 ROP when they were transferred from other hospitals.
Development of peripheral retinal laser photocoagulation has
resulted in decreasing the incidence of poor visual outcome, but the
sequential nature of ROP requires that at-risk preterm infants be
examined at appropriate times to detect the changes of ROP before
they become permanently destructive. Recently, intravitreal bev-
acizumab injection as monotherapy or combined therapy with
conventional laser therapy has become a new choice of treatment
in infants with stage 3þ ROP.44e46 It may further beneﬁt these
children in the long term. Long-term evaluations show that, with
less invasive procedures, these children will have better visual
outcomes, not only in visual acuity but also in eyeball structures
and subsequent refractive outcomes. In our clinical experience,
although there is a high percentage of ROP development in VLBW
infants, most of them would have sufﬁcient vision for their daily
activities in the long term.32
5. Conclusion
ROP is a disease that could result in severe visual impairment
and permanent blindness especially among low birth body weight
infants. In our study, we found that increased severity of ROP may
correlatewith lower gestational age, lower birth bodyweight, more
severe degree of RDS, and prolonged use of oxygen. Maternal
history of antenatal steroid use may correlate with less severity of
ROP. More risk factors associated with severity of ROP needs further
studies, and the most important thing about screening of ROP is
that eye ground examination should be performed at an appro-
priate time.
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